Overcoming mTOR Resistance in Renal Cell Carcinoma

February 4, 2014
Elizabeth Plimack, MD, MS

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).

Clinical Pearls

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).

  • This study represents the first step in a long process: testing the hypothesis that HDAC inhibition can overcome resistance to mTOR inhibition
  • Two patients treated with prior mTOR inhibitors progressed and then did well when treated with the combination of ridaforolimus and vorinostat
  • Ridaforolimus 20 mg once daily plus vorinostat 100 mg once daily will be tested in a larger trial in patients who had both prior mTOR inhibitors and those who did not

<<<

Back to the GU 2014 conference page